Your browser is no longer supported. Please, upgrade your browser.
IONS [NASD]
Ionis Pharmaceuticals, Inc.
Index- P/E124.05 EPS (ttm)0.49 Insider Own0.20% Shs Outstand139.71M Perf Week0.39%
Market Cap8.30B Forward P/E- EPS next Y-0.72 Insider Trans-52.30% Shs Float132.88M Perf Month19.02%
Income73.40M PEG- EPS next Q0.28 Inst Own86.70% Short Float5.44% Perf Quarter26.90%
Sales932.70M P/S8.90 EPS this Y572.90% Inst Trans-0.16% Short Ratio6.38 Perf Half Y-1.40%
Book/sh9.90 P/B6.19 EPS next Y-44.00% ROA2.30% Target Price65.37 Perf Year-0.29%
Cash/sh17.19 P/C3.56 EPS next 5Y- ROE5.30% 52W Range39.32 - 64.26 Perf YTD8.38%
Dividend- P/FCF46.61 EPS past 5Y52.40% ROI13.40% 52W High-4.64% Beta1.25
Dividend %- Quick Ratio10.30 Sales past 5Y39.30% Gross Margin99.00% 52W Low55.85% ATR2.42
Employees817 Current Ratio10.40 Sales Q/Q-4.60% Oper. Margin9.60% RSI (14)64.35 Volatility4.58% 4.26%
OptionableYes Debt/Eq0.59 EPS Q/Q-221.40% Profit Margin7.90% Rel Volume1.12 Prev Close61.35
ShortableYes LT Debt/Eq0.59 EarningsNov 04 BMO Payout0.00% Avg Volume1.13M Price61.28
Recom2.60 SMA206.55% SMA5015.99% SMA20013.69% Volume1,263,359 Change-0.11%
Dec-16-20Initiated UBS Sell $34
Dec-15-20Upgrade Cowen Market Perform → Outperform
Sep-14-20Resumed JP Morgan Neutral $63
Sep-02-20Initiated The Benchmark Company Hold
Jun-01-20Resumed Oppenheimer Outperform
May-13-20Initiated RBC Capital Mkts Outperform $71
Mar-05-20Initiated Citigroup Buy $73
Dec-13-19Initiated Oppenheimer Outperform
Nov-13-19Initiated BofA/Merrill Buy $70
Nov-07-19Downgrade Morgan Stanley Equal-Weight → Underweight $63 → $48
Sep-10-19Upgrade Bernstein Mkt Perform → Outperform
Aug-08-18Reiterated Stifel Hold $48 → $47
Aug-07-18Reiterated Stifel Hold $55 → $48
May-08-18Downgrade Evercore ISI Outperform → In-line
Oct-06-17Resumed Goldman Sell $30
Aug-17-17Initiated Evercore ISI Outperform $65
Aug-09-17Reiterated Stifel Hold $42 → $50
Mar-10-17Downgrade Goldman Neutral → Sell
Dec-28-16Reiterated BMO Capital Markets Outperform $61 → $68
Dec-27-16Reiterated Leerink Partners Mkt Perform $40 → $47
Jan-15-21 04:22PM  
04:19PM  
Jan-08-21 07:30AM  
Jan-07-21 05:30PM  
Jan-05-21 07:05AM  
Dec-23-20 02:03AM  
Dec-17-20 06:30PM  
Dec-08-20 09:15PM  
Dec-04-20 11:31AM  
Dec-02-20 07:05AM  
Dec-01-20 05:10PM  
07:05AM  
Nov-30-20 05:15PM  
Nov-23-20 05:15PM  
Nov-13-20 07:05AM  
Nov-12-20 07:05AM  
Nov-10-20 07:05AM  
Nov-09-20 07:05AM  
03:00AM  
Nov-08-20 08:28AM  
Nov-06-20 03:00AM  
Nov-05-20 09:57AM  
Nov-04-20 08:31PM  
12:00PM  
08:25AM  
07:24AM  
07:00AM  
06:42AM  
Nov-03-20 06:00PM  
Oct-30-20 07:00AM  
Oct-28-20 12:32PM  
Oct-23-20 02:05PM  
Oct-22-20 07:05AM  
Oct-21-20 07:05AM  
Oct-19-20 12:46PM  
Oct-15-20 07:05AM  
Oct-13-20 12:32PM  
Oct-12-20 09:00AM  
Oct-08-20 08:50AM  
Oct-07-20 04:54PM  
Oct-02-20 11:18AM  
Oct-01-20 04:05PM  
06:00AM  
Sep-30-20 04:05PM  
Sep-21-20 06:45PM  
Sep-04-20 11:31AM  
Sep-03-20 07:05AM  
Sep-02-20 05:10PM  
10:04AM  
Sep-01-20 10:14AM  
05:34AM  
Aug-31-20 08:10PM  
07:44PM  
06:56PM  
06:55AM  
Aug-29-20 04:00AM  
03:30AM  
Aug-26-20 07:05AM  
Aug-24-20 07:00AM  
Aug-18-20 07:00AM  
Aug-13-20 07:00AM  
Aug-06-20 09:21AM  
Aug-05-20 08:55AM  
07:47AM  
07:00AM  
Jul-30-20 07:32PM  
Jul-29-20 12:33PM  
Jul-27-20 02:39PM  
Jul-22-20 07:05AM  
Jul-21-20 07:00AM  
Jul-20-20 07:00AM  
Jul-17-20 03:31PM  
Jul-09-20 07:00AM  
Jul-07-20 07:05AM  
Jun-17-20 07:00AM  
Jun-16-20 09:48PM  
Jun-09-20 07:00AM  
Jun-05-20 07:05AM  
May-29-20 07:03AM  
01:50AM  
May-28-20 04:05PM  
07:00AM  
May-19-20 09:07AM  
May-18-20 07:00AM  
May-14-20 04:05PM  
May-13-20 08:00AM  
May-08-20 06:03AM  
May-07-20 07:00AM  
01:31AM  
May-06-20 09:45AM  
07:00AM  
May-05-20 04:05PM  
May-01-20 07:05AM  
Apr-29-20 12:34PM  
Apr-22-20 11:08AM  
07:05AM  
Apr-21-20 07:09AM  
07:00AM  
Apr-20-20 07:05AM  
Apr-13-20 09:18AM  
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It is involved in developing neurology products that include Tominersen for Huntington's diseases; Tofersen for amyotrophic lateral sclerosis (ALS); IONIS-MAPTRx for Alzheimer's diseases; IONIS-C9Rx for genetic from ALS; ION859 for Parkinson's disease; and IONIS-DNM2-2.5Rx for centronuclear myopathy. The company is also developing severe and rare disease products, such as AKCEA-TTR-LRx for transthyretin amyloidosis and IONIS-GHR-LRx for acromegaly; IONIS-PKK-LRx for hereditary angioedema; IONIS-TMPRSS6-LRx for beta-thalassemia and iron toxicity; IONIS-ENAC-2.5Rx for cystic fibrosis; and ION357 for retinitis pigmentosa. In addition, its cardio metabolic and renal drugs include AKCEA-APO(a)-LRx and AKCEA-APOCIII-LRx for cardiovascular diseases; AKCEA-ANGPTL3-LRx for cardio metabolic disorders; IONIS-GCGRRx for type 2 diabetes; IONIS-AGT-LRX for the treatment of resistant hyper tension; IONIS-FXI-LRx for clotting disorders; IONIS-AZ4-2.5-LRx for cardiovascular diseases; and ION839 for nonalcoholic steatohepatitis. Further, the company develops products for oncology that include IONIS-AR-2.5Rx and danvatirsen for cancers; IONIS-HBVRx and IONIS-HBV-LRx for hepatitis B virus infection; and IONIS-FB-LRx for compliment meditated disease. It has a collaboration agreement with AstraZeneca; Biogen Inc.; and Roche. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Geary Richard SEVP, Chief Development OffcJan 13Sale59.501418,39030,306Jan 15 05:55 PM
Swayze EricEVP, ResearchJan 05Sale55.9919510,9185,107Jan 06 09:23 PM
PARSHALL B LYNNEDirectorDec 23Sale60.0010,000600,00057,464Dec 28 05:29 PM
CROOKE STANLEY TExec Chairman of the BoardDec 17Sale50.501,40771,054174Dec 17 07:42 PM
CROOKE STANLEY TExec Chairman of the BoardDec 15Sale49.7839,0001,941,225600,391Dec 17 07:42 PM
CROOKE STANLEY TExec Chairman of the BoardDec 07Sale51.6711,000568,351639,391Dec 09 08:14 PM
BENNETT C FRANKChief Scientific OfficerDec 04Option Exercise39.877,947316,84740,423Dec 08 08:49 PM
Monia Brett PChief Executive OfficerDec 04Option Exercise39.8723,840950,50152,719Dec 08 08:51 PM
Monia Brett PChief Executive OfficerDec 04Sale51.0423,8401,216,79428,879Dec 08 08:51 PM
BENNETT C FRANKChief Scientific OfficerDec 04Sale51.047,947405,61532,476Dec 08 08:49 PM
Monia Brett PChief Executive OfficerDec 02Option Exercise39.8721,160843,64950,039Dec 04 08:49 PM
BENNETT C FRANKChief Scientific OfficerDec 02Option Exercise39.877,053281,20339,529Dec 04 08:53 PM
BENNETT C FRANKChief Scientific OfficerDec 02Sale51.327,053361,96032,476Dec 04 08:53 PM
Monia Brett PChief Executive OfficerDec 02Sale51.3221,1601,085,93128,879Dec 04 08:49 PM
Geary Richard SEVP, DevelopmentNov 25Option Exercise39.8711,920475,25042,367Nov 30 06:46 PM
CROOKE STANLEY TExec Chairman of the BoardNov 25Option Exercise39.8712,990517,91115,011Nov 30 06:48 PM
HOUGEN ELIZABETH LEVP, Finance & CFONov 25Option Exercise39.8721,680864,38254,175Nov 30 06:49 PM
PARSHALL B LYNNEDirectorNov 25Option Exercise39.873,590143,13371,054Nov 30 06:44 PM
HOUGEN ELIZABETH LEVP, Finance & CFONov 25Sale50.0521,6801,085,08432,495Nov 30 06:49 PM
CROOKE STANLEY TExec Chairman of the BoardNov 25Sale50.0512,990650,1502,021Nov 30 06:48 PM
Geary Richard SEVP, DevelopmentNov 25Sale50.0511,920596,59630,447Nov 30 06:46 PM
PARSHALL B LYNNEDirectorNov 25Sale50.053,590179,68067,464Nov 30 06:44 PM
PARSHALL B LYNNEDirectorNov 24Option Exercise39.8771028,30868,174Nov 25 06:56 PM
Geary Richard SEVP, DevelopmentNov 24Option Exercise39.872,38094,89132,827Nov 25 06:58 PM
HOUGEN ELIZABETH LEVP, Finance & CFONov 24Option Exercise39.874,320172,23836,815Nov 25 07:02 PM
CROOKE STANLEY TExec Chairman of the BoardNov 24Option Exercise39.872,590103,2634,611Nov 25 07:04 PM
CROOKE STANLEY TExec Chairman of the BoardNov 24Sale50.832,590131,6502,021Nov 25 07:04 PM
HOUGEN ELIZABETH LEVP, Finance & CFONov 24Sale50.834,320219,58632,495Nov 25 07:02 PM
Geary Richard SEVP, DevelopmentNov 24Sale50.832,380120,97530,447Nov 25 06:58 PM
PARSHALL B LYNNEDirectorNov 24Sale50.8271036,08267,464Nov 25 06:56 PM
PARSHALL B LYNNEDirectorNov 23Option Exercise39.873,200127,58470,664Nov 25 06:56 PM
Geary Richard SEVP, DevelopmentNov 23Option Exercise39.8710,700426,60941,147Nov 25 06:58 PM
HOUGEN ELIZABETH LEVP, Finance & CFONov 23Option Exercise39.8719,000757,53045,620Nov 25 07:02 PM
CROOKE STANLEY TExec Chairman of the BoardNov 23Option Exercise39.8750019,9352,081Nov 25 07:04 PM
CROOKE STANLEY TExec Chairman of the BoardNov 23Option Exercise39.8711,600462,49213,621Nov 25 07:04 PM
CROOKE STANLEY TExec Chairman of the BoardNov 23Sale50.0050025,0001,581Nov 25 07:04 PM
CROOKE STANLEY TExec Chairman of the BoardNov 23Sale50.1111,600581,2762,021Nov 25 07:04 PM
HOUGEN ELIZABETH LEVP, Finance & CFONov 23Sale50.1119,000952,09032,495Nov 25 07:02 PM
Geary Richard SEVP, DevelopmentNov 23Sale50.1110,700536,17730,447Nov 25 06:58 PM
PARSHALL B LYNNEDirectorNov 23Sale50.123,200160,38467,464Nov 25 06:56 PM
BENNETT C FRANKChief Scientific OfficerNov 03Option Exercise39.8715,000598,05047,476Nov 05 08:26 PM
BENNETT C FRANKChief Scientific OfficerNov 03Sale46.7715,000701,60032,476Nov 05 08:26 PM
KLEIN JOSEPH IIIDirectorOct 20Sale46.862,889135,38613,794Oct 22 05:36 PM
Hayden Michael RDirectorOct 15Option Exercise0.001,77805,334Oct 19 05:50 PM
Reikes Peter NDirectorOct 15Option Exercise0.001,77805,334Oct 19 05:46 PM
CROOKE STANLEY TExec Chairman of the BoardSep 22Sale50.4150,0002,520,460650,391Sep 23 06:44 PM
CROOKE STANLEY TExec Chairman of the BoardSep 21Sale50.182,000100,3601,581Sep 23 06:44 PM
WENDER JOSEPH HDirectorSep 16Option Exercise20.7122,500465,86388,305Sep 18 05:45 PM
Monia Brett PChief Executive OfficerSep 01Sale53.7031416,86228,879Sep 02 07:01 PM
LOSCALZO JOSEPHDirectorJul 06Option Exercise0.00667017,308Jul 06 05:49 PM
KLEIN JOSEPH IIIDirectorJul 06Option Exercise0.00667016,683Jul 06 05:32 PM
WENDER JOSEPH HDirectorJul 06Option Exercise0.00667065,805Jul 06 05:26 PM
Castleman BreauxDirectorJul 06Option Exercise0.00667019,183Jul 06 05:30 PM
BERTHELSEN SPENCER RDirectorJul 06Option Exercise0.006670100,983Jul 06 05:25 PM
MUTO FREDERICK TDirectorJul 06Option Exercise0.00667031,683Jul 06 05:23 PM
MUTO FREDERICK TDirectorJul 02Option Exercise0.00889031,016Jul 06 05:23 PM
BERTHELSEN SPENCER RDirectorJul 02Option Exercise0.008890100,316Jul 06 05:25 PM
Castleman BreauxDirectorJul 02Option Exercise0.00889018,516Jul 06 05:30 PM
WENDER JOSEPH HDirectorJul 02Option Exercise0.00889065,138Jul 06 05:26 PM
KLEIN JOSEPH IIIDirectorJul 02Option Exercise0.00889016,016Jul 06 05:32 PM
PARSHALL B LYNNEDirectorJul 02Option Exercise0.00889067,464Jul 06 05:47 PM
LOSCALZO JOSEPHDirectorJul 02Option Exercise0.00889016,641Jul 06 05:49 PM
LOSCALZO JOSEPHDirectorJul 01Option Exercise0.002,444015,752Jul 06 05:49 PM
PARSHALL B LYNNEDirectorJul 01Option Exercise0.001,778066,575Jul 06 05:47 PM
KLEIN JOSEPH IIIDirectorJul 01Option Exercise0.002,444015,127Jul 06 05:32 PM
WENDER JOSEPH HDirectorJul 01Option Exercise0.002,444064,249Jul 06 05:26 PM
Hayden Michael RDirectorJul 01Option Exercise0.001,77803,556Jul 06 06:48 PM
HERMAN JOAN EDirectorJul 01Option Exercise0.001,77805,334Jul 06 05:51 PM
Castleman BreauxDirectorJul 01Option Exercise0.002,444017,627Jul 06 05:30 PM
Reikes Peter NDirectorJul 01Option Exercise0.001,77803,556Jul 06 05:28 PM
BERTHELSEN SPENCER RDirectorJul 01Option Exercise0.002,444099,427Jul 06 05:25 PM
MUTO FREDERICK TDirectorJul 01Option Exercise0.002,444030,127Jul 06 05:23 PM
MUTO FREDERICK TDirectorJun 30Option Exercise9.2215,000138,30027,683Jul 02 05:11 PM
BENNETT C FRANKEVP, Chief Scientific OfficerJun 25Option Exercise39.8715,000598,05047,364Jun 29 09:47 PM
Castleman BreauxDirectorJun 25Option Exercise26.6610,000266,60025,183Jun 29 09:47 PM
BENNETT C FRANKEVP, Chief Scientific OfficerJun 25Sale59.7715,000896,50532,364Jun 29 09:47 PM
Castleman BreauxDirectorJun 25Sale60.0010,000600,00015,183Jun 29 09:47 PM
CROOKE STANLEY TExec Chairman of the BoardJun 25Sale60.119,914595,9072,021Jun 26 07:47 PM
CROOKE STANLEY TExec Chairman of the BoardJun 24Sale58.805,000294,00011,935Jun 26 07:47 PM
BERTHELSEN SPENCER RDirectorJun 23Option Exercise9.2215,000138,300111,983Jun 25 07:28 PM
BERTHELSEN SPENCER RDirectorJun 23Sale58.7615,000881,40096,983Jun 25 07:28 PM
CROOKE STANLEY TExec Chairman of the BoardJun 19Sale58.3310,000583,25016,935Jun 19 07:03 PM
CROOKE STANLEY TExec Chairman of the BoardJun 17Sale58.252,000116,5003,581Jun 19 07:03 PM
CROOKE STANLEY TExec Chairman of the BoardJun 17Sale57.9015,000868,52126,935Jun 19 07:03 PM
HERMAN JOAN EDirectorJun 10Option Exercise0.003,55603,556Jun 17 08:15 PM
CROOKE STANLEY TExec Chairman of the BoardMar 25Sale47.001,00047,0005,581Mar 27 07:05 PM
CROOKE STANLEY TExec Chairman of the BoardMar 25Sale47.0015,000705,00041,935Mar 27 07:05 PM
CROOKE STANLEY TExec Chairman of the BoardMar 19Sale45.001,00045,0006,581Mar 23 06:17 PM
CROOKE STANLEY TExec Chairman of the BoardMar 19Sale45.1715,000677,54656,545Mar 23 06:17 PM
CROOKE STANLEY TExec Chairman of the BoardMar 17Sale44.7520,390912,35571,545Mar 19 01:55 PM
O'NEIL PATRICK R.SVP & General CounselFeb 10Sale59.603,882231,36720,720Feb 11 05:40 PM